PTPRK and neoplasm: Furthermore, as reported in other tumors types, upregulation of DAB2 [72], RND3 [73, 74], TMEM97 [75], CSE1L [76], MYO1C [77], and PTPRK [78] have been shown to suppress or functionally redistribute E-cadherin expression in cancer cells, resulting in EMT, increased invasion, advanced tumor stage and poor patient survival.